创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

朱凌峰, 王中健. 全球基因治疗药物研发现状分析[J]. 药学进展, 2022, 46(5): 325-338.
引用本文: 朱凌峰, 王中健. 全球基因治疗药物研发现状分析[J]. 药学进展, 2022, 46(5): 325-338.
ZHU Lingfeng, WANG Zhongjian. Analysis of Global Gene Therapy Drug Development Status[J]. Progress in Pharmaceutical Sciences, 2022, 46(5): 325-338.
Citation: ZHU Lingfeng, WANG Zhongjian. Analysis of Global Gene Therapy Drug Development Status[J]. Progress in Pharmaceutical Sciences, 2022, 46(5): 325-338.

全球基因治疗药物研发现状分析

Analysis of Global Gene Therapy Drug Development Status

  • 摘要: 随着DNA重组、基因克隆等技术的逐步成熟,基因治疗这一具有革命性的医疗技术不断发展,改变了单基因遗传病的治疗现状,为肿瘤、遗传性疾病、自身免疫性疾病等带来了新的选择。截至2022年2月,全球已有37款基因治疗药物获批上市。通过对1998年至2022年2月全球范围内获批上市的基因治疗药物进行数据监控与分析,包括药物分类、药物名称、适应证、批准日期、批准国家、研发公司等,并且对全球在研基因治疗药物的研发现状进行分析总结,以期为基因治疗药物的立项与研发提供参考。

     

    Abstract: With the maturity of DNA recombination technology and gene cloning technology, gene therapy, a revolutionary medical technology, continues to develop, changing the treatment status of single-gene genetic diseases with new options for tumors, genetic diseases and autoimmune diseases. As of February 2022, 37 gene therapy drugs have been approved worldwide. Through data monitoring and analysis of gene therapy drugs approved for marketing worldwide from 1998 to 2022, including drug names, indications, approval dates, approved countries, companies and other information, the classification of marketed gene therapy drugs and the global research and development status of each drug were analyzed and summarized to provide reference for the research on gene therapy drug development.

     

/

返回文章
返回